Evidence map›Paper›PMID 40299201›Full record

ArticleProbiotics and antimicrobial proteins2026

Characteristics and Antibacterial Activity of Staphylococcus aureus Phage-Derived Endolysin LysP4.

Mingming Gao, Xinting Yu, Cuiping Yang, Zhiqiang Mi, Changqing Bai, Chuanbin Liu, Huiying Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Isolation and characterization of a novelFrontiers in cellular and infection microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mingming Gao *Chinese PLA General Hospital, Beijing, 100853, China.
Xinting Yu *Mianyang Central Hospital, Mianyang, 621000, Sichuan, China.
Cuiping Yang *College of Pulmonary and Critical Care Medicine, The 8th Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China.
Zhiqiang MiState Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China.
Changqing BaiDepartment of Respiratory and Critical Care Diseases, General Hospital of Shenzhen University, Shenzhen, 518055, China.
Chuanbin LiuWestern Medical Branch of PLA General Hospital, Beijing, 100853, China. doctor_liuchuanbin@126.com.
Huiying LiuCollege of Pulmonary and Critical Care Medicine, The 8th Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China. liuhuiying1982@sina.com.

Funding

Beijing Natural Science Foundation of China L232125The National Natural Science Foundation of China 82170087
6 · The paper itself

Abstract

The rise in multidrug resistance and strong biofilm-forming ability of Staphylococcus aureus has led to significant public health concerns. Phage or phage-derived components, such as depolymerase or endolysin, have been considered as potential alternatives to antibiotics for combating antibiotic-resistant bacterial infections. In this study, we cloned and expressed a Staphylococcus aureus phage endolysin, LysP4, and identified its lytic activity. The bactericidal effect of LysP4 was more pronounced against planktonic cells in the logarithmic phase compared to those in the stationary phase. LysP4 reduces bacterial counts by 3 log CFU/mL in 60 min and about 2 log CFU/mL during the stationary phase. LysP4 exhibited optimal lytic activity at pH 5.0-7.0 and remained stable across a temperature range of 16 to 40 °C, with maximal activity observed at 37 °C. LysP4 effectively targets 31 of 38 Staphylococcus strains and successfully eliminates biofilms, reducing bacterial counts by 4 log CFU/mL when combined with vancomycin. Notably, LysP4 demonstrated no hemolytic effects on human red blood cells and no toxic effects on embryonic kidney cells or lung cancer cells. Based on these findings, we believe that LysP4 holds promise as a biological control agent against Staphylococcus infections.

Indexed as

Anti-Bacterial AgentsEndopeptidasesStaphylococcus aureusStaphylococcus PhagesViral ProteinsBiofilmsHumansMicrobial Sensitivity TestsStaphylococcal InfectionsAnti-Bacterial AgentsendolysinEndopeptidasesViral ProteinsBacteriophageBiofilmsEndolysinStaphylococcus aureus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.